Elicio Therapeutics ELTX Institutional Ownership

Ownership Summary

Elicio Therapeutics, Inc. (NASDAQ:ELTX) appears in 47 institutional 13F filings for the quarter ending March 2026.

• Collectively, these holders controlled 14.5% of Elicio Therapeutics's outstanding shares in March 2026, up from 13.6% in December 2025.
• Their total shares held in ELTX increased 73.79% quarter over quarter, and separately, investors owning Elicio Therapeutics increased 88.0% from a year ago.
• During the quarter, 32 of these 47 funds increased positions in ELTX, 6 reduced exposure, and 9 held steady.
• Combined, these investors held 2.64Mn shares in ELTX for March 2026, up by 1.12Mn shares quarter on quarter, and up 996.84K shares year over year.
• As of March 31, 2026, the biggest holder of Elicio Therapeutics is Knoll Capital Management, LLC at 630.92K shares, representing 3.46% of shares outstanding.
• The largest buyers of Elicio Therapeutics for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (518.64K), BALYASNY ASSET MANAGEMENT L.P. (106.05K), RENAISSANCE TECHNOLOGIES LLC (93.52K), MILLENNIUM MANAGEMENT LLC (92.76K), VANGUARD FIDUCIARY TRUST CO (69.19K).
• The biggest sellers of Elicio Therapeutics for the quarter ending March 2026 included MARSHALL WACE, LLP (42.69K), OMERS ADMINISTRATION Corp (12.8K), Qube Research & Technologies Ltd (7.73K), Quadrature Capital Ltd (247), Royal Bank Of Canada (196).
• Per Business Quant, the top 10 investors in ELTX for the quarter ending March 2026 include Knoll Capital Management, LLC (630.92K), VANGUARD CAPITAL MANAGEMENT LLC (518.64K), BALYASNY ASSET MANAGEMENT L.P. (244.81K), GEODE CAPITAL MANAGEMENT, LLC (135.16K), RENAISSANCE TECHNOLOGIES LLC (121.63K), MILLENNIUM MANAGEMENT LLC (92.76K), MARSHALL WACE, LLP (74.51K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (70.8K), VANGUARD FIDUCIARY TRUST CO (69.19K), Northern Trust Corp (59.73K).